Equibles does not estimate personal net worth.
Earlier roles on record: CEO at Emergent BioSolutions Inc. (EBS) until June 24, 2023. Emergent BioSolutions Inc. reported in an 8-K filed June 27, 2023 that Bob Kramer resigned as director, effective June 24, 2023. Emergent BioSolutions Inc. reported in an 8-K filed June 27, 2023 that Bob Kramer resigned as President and Chief Executive Officer, effective June 24, 2023. Bob Kramer has spoken on 28 earnings calls across 1 company, most recently for Emergent BioSolutions Inc. on May 9, 2023. The companies whose calls Bob Kramer spoke on are classified in the Healthcare sector.
“On June 23, 2023, Robert G. Kramer Sr. notified the Board of Directors (the "Board") of Emergent BioSolutions, Inc. (the "Company") of his intent to retire from the Company on August 1, 2023 and to resign from his positions as President and Chief Executive Officer and as a director, effective June 24, 2023.”
“On June 23, 2023, Robert G. Kramer Sr. notified the Board of Directors (the "Board") of Emergent BioSolutions, Inc. (the "Company") of his intent to retire from the Company on August 1, 2023 and to resign from his positions as President and Chief Executive Officer and as a director, effective June 24, 2023.”
“I invite in a minute here, Paul, to weigh in. But as we announced our guidance initially for 2023, we made it clear that our plans included an OTC switch sometime in Q3 of this year.”
“A summary of my remarks begins on page six. As you have read in our press release, our fourth quarter and fiscal year 2022 results are largely in line with the guidance that we provided at the end of last year and then reaffirmed again in our January 9th press release.”
“Today, we'll provide an update on our business, including significant recent developments, as well as thoughts on the road ahead for Emergent. Let me first begin with our medical countermeasures business, which, as you all know, is a cornerstone of our strategy.”
“I want to provide you with a recap of our accomplishments last quarter and update you as well on our progress to year-to-date progress. My comments are summarized on Slide 7 of the deck.”
“And good afternoon, and thank you to everyone for joining the call. I’m pleased to share details about our performance and progress in the first quarter. And as Bob indicated, my comments are summarized on slide 7 of the deck.”
Start not stated–2023-06-24
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
